Compare AbCellera Biologics Inc (ABCL) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs JPMorgan Diversified Return International Eqty ETF — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while JPMorgan Diversified Return International Eqty ETF trades at $72.26. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, JPMorgan Diversified Return International Eqty ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | JPIN | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $76.96 |
52-Week Low | $2.78 | $63.14 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
JPIN trades at $73.74, up 0.49% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides broad exposure to international value stocks. A dividend of $0.91 per share is scheduled for payment on June 25, 2026.
Outlook remains cautiously optimistic given bullish technical trends, though overbought RSI signals near-term risk. Key risks include international market volatility and currency fluctuations. The dividend provides income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
